Wells Fargo’s Impact BioMedical IBO Stock Holding History

Wells Fargo’s Portfolio IBO Stock Details IBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$103	Hold	224	–	–	﹤0.01%	6641
2026 Q1	$134	Hold	224	–	–	﹤0.01%	6481
2025 Q4	$113	Sell	224 -29	-11%	-$15	﹤0.01%	6420
2025 Q3	$168	Buy	253 +224	+772%	+$141	﹤0.01%	6355
2025 Q2	$19	Sell	29 -1,000	-97%	-$561	﹤0.01%	6801
2025 Q1	$895	Buy	1,029 +1,000	+3,448%	+$1.73K	﹤0.01%	6245
2024 Q4	$42	Hold	29	–	–	﹤0.01%	6535
2024 Q3	$58	Buy	+29	New	+$69	﹤0.01%	6335

Other funds holding IBO

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Global Advisers Malvern, Pennsylvania $215B AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Wells Fargo's IBO Position: Q2 2026 in Review

Wells Fargo held its Impact BioMedical (IBO) position steady in Q2 2026 at 224 shares worth $103. The position accounts for ﹤0.01% of the portfolio, ranked #6641.

Wells Fargo first reported a position in IBO in Q3 2024 and has held it in 8 quarters since. The position peaked at $895 in Q1 2025. 22 funds tracked by Wall St. Rank hold IBO as of Q2 2026.

Wells Fargo held 224 shares of Impact BioMedical worth $103 as of Q2 2026.
Wells Fargo left its Impact BioMedical share count unchanged in Q2 2026.
Impact BioMedical made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #6641 holding.
Wells Fargo first reported a position in Impact BioMedical in Q3 2024 and has held it in 8 quarters since.
Wells Fargo's Impact BioMedical position peaked at $895 in Q1 2025.
22 funds tracked by Wall St. Rank held Impact BioMedical as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.